<p>Galapagos NV（纳斯达克代码：GLPG - 获取免费报告）在三月份的空头头寸显著增加。截至 3 月 31 日，空头头寸总计为 1,096,114 股，比 3 月 15 日的 910,692 股增加了 20.4%。该股票约有 1.7% 的股份被做空。根据平均交易量 218,377 股，目前的覆盖天数比率为 5.0 天。</p>
<h2>Galapagos 价格表现</h2>
<p>在周五的交易中，Galapagos 股票上涨了 0.42 美元，达到 29.28 美元。该公司交易了 91,131 股，较其平均交易量 207,593 股有所减少。Galapagos 的 52 周低点为 24.31 美元，52 周高点为 37.78 美元。该公司的市值为 19.3 亿美元，市盈率为-18.65，贝塔值为 0.32。该股票的 50 日简单移动平均线为 31.77 美元，200 日简单移动平均线为 32.38 美元。</p>
<p>Galapagos（纳斯达克代码：GLPG - 获取免费报告）最近于 2 月 15 日公布了季度财报。该生物技术公司报告本季度每股收益为 13.92 美元。该公司本季度的收入为 10.6 亿美元。整体来看，股票分析师预测 Galapagos 在当前年度的每股收益为-1.6。</p>
<h2>机构投资者对 Galapagos 的看法</h2>
<p>几家对冲基金和其他机构投资者最近增加或减少了对 GLPG 的持股。Ameriprise Financial Inc.在第三季度将其在 Galapagos 的持股增加了 2490.1%。Ameriprise Financial Inc.目前拥有 1,416,934 股该生物技术公司的股票，价值 49,083,000 美元，此前在上个季度增持了 1,362,229 股。瑞银集团在第四季度将其在 Galapagos 的持股增加了 128.4%。瑞银集团目前拥有 349,444 股该生物技术公司的股票，价值 11,427,000 美元，此前在上个季度增持了 196,445 股。Millennium Management LLC 在第四季度将其在 Galapagos 的持股增加了 121.9%。Millennium Management LLC 目前拥有 339,354 股该生物技术公司的股票，价值 11,097,000 美元，此前在上个季度增持了 186,452 股。Jane Street Group LLC 在第一季度将其在 Galapagos 的持股增加了 2245.7%。Jane Street Group LLC 目前拥有 110,783 股该生物技术公司的股票，价值 2,783,000 美元，此前在上个季度增持了 115,946 股。最后，Kotler Kevin 在第四季度新购入了价值 2,943,000 美元的 Galapagos 股份。机构投资者和对冲基金持有该公司 32.46% 的股份。</p>
<h2>分析师评级变动</h2>
<p>多家券商最近对 GLPG 发表了评论。加拿大皇家银行在 2 月 24 日的研究报告中将 Galapagos 的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 “行业表现” 评级。Raymond James Financial 在 2 月 24 日的研究报告中重申了对 Galapagos 股票的 “市场表现” 评级。华尔街 Zen 在 3 月 28 日的研究报告中将 Galapagos 的评级从 “持有” 上调至 “买入”。Weiss Ratings 在 2 月 26 日的研究报告中将 Galapagos 的评级从 “卖出（d）” 上调至 “持有（c）”。最后，瑞银集团在 2 月 24 日的研究报告中重申了对 Galapagos 股票的 “市场表现” 评级。一位研究分析师给予该股票 “强烈买入” 评级，五位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 36.50 美元。</p>
<p><strong>查看我们最新的 Galapagos 股票报告</strong></p>
<h2>关于 Galapagos</h2>
<p>（获取免费报告）</p>
<p>Galapagos NV（纳斯达克代码：GLPG）是一家总部位于比利时梅赫伦的临床阶段生物技术公司，专注于新型小分子疗法的发现和开发。该公司于 1999 年通过 Tibotec 和 Progenix 的合并成立，建立了针对慢性炎症性疾病、纤维化和肿瘤学的研究平台。公司的发现引擎整合了人类遗传学、转化生物学和药物化学，以识别和优化具有独特作用机制的药物候选者。</p>
<p>该公司的产品管线涵盖多个不同开发阶段的项目。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票，胜过 Galapagos</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Galapagos 吗？</h2>
<p>在考虑 Galapagos 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而 Galapagos 并不在名单上。</p>
<p>虽然 Galapagos 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

GLPG

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

<p>Galapagos NV（纳斯达克代码：GLPG）在 3 月份的空头头寸增加了 20.4%，截至 3 月 31 日，总计为 1,096,114 股。这代表公司股票的 1.7% 被做空，基于每日平均交易量 218,377 股，空头头寸比率为 5.0 天。该股票的交易价格为 29.28 美元，市值为 19.3 亿美元。分析师的评级意见不一，普遍评级为 “持有”，目标价格为 36.50 美元。机构投资者持有该股票的 32.46%，显示出对公司的显著兴趣</p>

<p>Galapagos NV (NASDAQ:GLPG - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totaling 1,096,114 shares, an increase of 20.4% from the March 15th total of 910,692 shares. Approximately 1.7% of the shares of the stock are short sold. Based on an average trading volume of 218,377 shares, the days-to-cover ratio is presently 5.0 days.</p>
<div class="lb-trans"><p>Galapagos NV（纳斯达克代码：GLPG - 获取免费报告）在三月份的空头头寸显著增加。截至 3 月 31 日，空头头寸总计为 1,096,114 股，比 3 月 15 日的 910,692 股增加了 20.4%。该股票约有 1.7% 的股份被做空。根据平均交易量 218,377 股，目前的覆盖天数比率为 5.0 天。</p>
</div><h2>Galapagos Price Performance</h2>
<div class="lb-trans"><h2>Galapagos 价格表现</h2>
</div><p>Galapagos stock traded up $0.42 during trading on Friday, reaching $29.28. 91,131 shares of the company were exchanged, compared to its average volume of 207,593. Galapagos has a 52-week low of $24.31 and a 52-week high of $37.78. The company has a market capitalization of $1.93 billion, a P/E ratio of -18.65 and a beta of 0.32. The stock's 50 day simple moving average is $31.77 and its two-hundred day simple moving average is $32.38.</p>
<div class="lb-trans"><p>在周五的交易中，Galapagos 股票上涨了 0.42 美元，达到 29.28 美元。该公司交易了 91,131 股，较其平均交易量 207,593 股有所减少。Galapagos 的 52 周低点为 24.31 美元，52 周高点为 37.78 美元。该公司的市值为 19.3 亿美元，市盈率为-18.65，贝塔值为 0.32。该股票的 50 日简单移动平均线为 31.77 美元，200 日简单移动平均线为 32.38 美元。</p>
</div><p>Galapagos (NASDAQ:GLPG - Get Free Report) last announced its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The company had revenue of $1.06 billion for the quarter. As a group, equities analysts forecast that Galapagos will post -1.6 earnings per share for the current year.</p>
<div class="lb-trans"><p>Galapagos（纳斯达克代码：GLPG - 获取免费报告）最近于 2 月 15 日公布了季度财报。该生物技术公司报告本季度每股收益为 13.92 美元。该公司本季度的收入为 10.6 亿美元。整体来看，股票分析师预测 Galapagos 在当前年度的每股收益为-1.6。</p>
</div><h2>Institutional Investors Weigh In On Galapagos</h2>
<div class="lb-trans"><h2>机构投资者对 Galapagos 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in GLPG. Ameriprise Financial Inc. increased its stake in Galapagos by 2,490.1% during the third quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company's stock worth $49,083,000 after acquiring an additional 1,362,229 shares during the last quarter. UBS Group AG increased its stake in Galapagos by 128.4% during the fourth quarter. UBS Group AG now owns 349,444 shares of the biotechnology company's stock worth $11,427,000 after acquiring an additional 196,445 shares during the last quarter. Millennium Management LLC increased its stake in Galapagos by 121.9% during the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company's stock worth $11,097,000 after acquiring an additional 186,452 shares during the last quarter. Jane Street Group LLC increased its stake in Galapagos by 2,245.7% during the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company's stock worth $2,783,000 after acquiring an additional 115,946 shares during the last quarter. Finally, Kotler Kevin acquired a new stake in Galapagos during the fourth quarter worth $2,943,000. Institutional investors and hedge funds own 32.46% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近增加或减少了对 GLPG 的持股。Ameriprise Financial Inc.在第三季度将其在 Galapagos 的持股增加了 2490.1%。Ameriprise Financial Inc.目前拥有 1,416,934 股该生物技术公司的股票，价值 49,083,000 美元，此前在上个季度增持了 1,362,229 股。瑞银集团在第四季度将其在 Galapagos 的持股增加了 128.4%。瑞银集团目前拥有 349,444 股该生物技术公司的股票，价值 11,427,000 美元，此前在上个季度增持了 196,445 股。Millennium Management LLC 在第四季度将其在 Galapagos 的持股增加了 121.9%。Millennium Management LLC 目前拥有 339,354 股该生物技术公司的股票，价值 11,097,000 美元，此前在上个季度增持了 186,452 股。Jane Street Group LLC 在第一季度将其在 Galapagos 的持股增加了 2245.7%。Jane Street Group LLC 目前拥有 110,783 股该生物技术公司的股票，价值 2,783,000 美元，此前在上个季度增持了 115,946 股。最后，Kotler Kevin 在第四季度新购入了价值 2,943,000 美元的 Galapagos 股份。机构投资者和对冲基金持有该公司 32.46% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages recently commented on GLPG. Royal Bank Of Canada lifted their price objective on Galapagos from $32.00 to $33.00 and gave the stock a &#34;sector perform&#34; rating in a research report on Tuesday, February 24th. Raymond James Financial reiterated a &#34;market perform&#34; rating on shares of Galapagos in a research report on Tuesday, February 24th. Wall Street Zen upgraded Galapagos from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 28th. Weiss Ratings upgraded Galapagos from a &#34;sell (d)&#34; rating to a &#34;hold (c)&#34; rating in a research report on Thursday, February 26th. Finally, UBS Group reiterated a &#34;market perform&#34; rating on shares of Galapagos in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $36.50.</p>
<div class="lb-trans"><p>多家券商最近对 GLPG 发表了评论。加拿大皇家银行在 2 月 24 日的研究报告中将 Galapagos 的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 “行业表现” 评级。Raymond James Financial 在 2 月 24 日的研究报告中重申了对 Galapagos 股票的 “市场表现” 评级。华尔街 Zen 在 3 月 28 日的研究报告中将 Galapagos 的评级从 “持有” 上调至 “买入”。Weiss Ratings 在 2 月 26 日的研究报告中将 Galapagos 的评级从 “卖出（d）” 上调至 “持有（c）”。最后，瑞银集团在 2 月 24 日的研究报告中重申了对 Galapagos 股票的 “市场表现” 评级。一位研究分析师给予该股票 “强烈买入” 评级，五位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 36.50 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Galapagos</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Galapagos 股票报告</strong></p>
</div><h2>About Galapagos</h2>
<div class="lb-trans"><h2>关于 Galapagos</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Galapagos NV NASDAQ: GLPG is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company's discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.</p>
<div class="lb-trans"><p>Galapagos NV（纳斯达克代码：GLPG）是一家总部位于比利时梅赫伦的临床阶段生物技术公司，专注于新型小分子疗法的发现和开发。该公司于 1999 年通过 Tibotec 和 Progenix 的合并成立，建立了针对慢性炎症性疾病、纤维化和肿瘤学的研究平台。公司的发现引擎整合了人类遗传学、转化生物学和药物化学，以识别和优化具有独特作用机制的药物候选者。</p>
</div><p>The company's pipeline encompasses multiple programs across various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线涵盖多个不同开发阶段的项目。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Galapagos</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Galapagos</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Galapagos Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Galapagos 吗？</h2>
</div><p>Before you consider Galapagos, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Galapagos 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而 Galapagos 并不在名单上。</p>
</div><p>While Galapagos currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Galapagos 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Galapagos NV（NASDAQ:GLPG）的空头头寸增加了 20.4%